Clinical trial

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

NCT06735248

Study summary

ClinicalTrials.gov

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years

Design: INTERVENTIONAL · Status: RECRUITING · Phase: PHASE2

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

BIOLOGICAL · Unmapped registry intervention mRNA-1195 Find medicine records · Find other trials using this name

BIOLOGICAL · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusRECRUITING

Study typeINTERVENTIONAL

Start date2025-04-16

PhasePHASE2

Conditions

Multiple Sclerosisverified · MONDO: multiple sclerosis

Interventions

mRNA-1195BIOLOGICAL

PlaceboBIOLOGICAL

Sponsors & collaborators

ModernaTX, Inc.lead sponsor

Mapped research locations

LondonUnited Kingdom2 BostonMassachusetts, United States1 DallasTexas, United States1 St LouisMissouri, United States1 Oklahoma CityOklahoma, United States1 GlasgowUnited Kingdom1 El PasoTexas, United States1 SheffieldUnited Kingdom1 Farmington HillsMichigan, United States1 EdinburghUnited Kingdom1 PlanoTexas, United States1 Newcastle upon TyneUnited Kingdom1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT06735248 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.